TITLE

Eflornithine Is Safer than Melarsoprol for the Treatment of Second-Stage Trypanosoma brucei gambiense Human African Trypanosomiasis

AUTHOR(S)
Chappuis, François; Udayraj, Nitya; Stietenroth, Kai; Meussen, Ann; Bovier, Patrick A.
PUB. DATE
September 2005
SOURCE
Clinical Infectious Diseases;9/1/2005, Vol. 41 Issue 5, p748
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kin, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with melarsoprol in 2001 and 2002 (n = 708).
ACCESSION #
17849579

 

Related Articles

  • Estimating the burden of rhodesiense sleeping sickness during an outbreak in Serere, eastern Uganda. Fèvre, Eric M.; Odiit, Martin; Coleman, Paul G.; Woolhouse, Mark E. J.; Welburn, Susan C. // BMC Public Health;2008, Vol. 8 Issue 1, p96 

    Background: Zoonotic sleeping sickness, or HAT (Human African Trypanosomiasis), caused by infection with Trypanosoma brucei rhodesiense, is an under-reported and neglected tropical disease. Previous assessments of the disease burden expressed as Disability-Adjusted Life Years (DALYs) for this...

  • Infectious disease: Genomics decodes drug action. Fairlamb, Alan H. // Nature;2/9/2012, Vol. 482 Issue 7384, p167 

    The article presents a genome-wide study that uses RNA interference in providing valuable insight on the drugs used to treat African trypanosomiasis or sleeping sickness caused by the single-celled parasite Trypanosoma brucei gambiense and T. b. rhodesiense. It mentions that among the drugs used...

  • Cerebrospinal Fluid Neopterin as Marker of the Meningo-Encephalitic Stage of Trypanosoma brucei gambiense Sleeping Sickness. Tiberti, Natalia; Hainard, Alexandre; Lejon, Veerle; Courtioux, Bertrand; Matovu, Enock; Enyaru, John Charles; Robin, Xavier; Turck, Natacha; Kristensson, Krister; Ngoyi, Dieudonné Mumba; Vatunga, Gedeão M. L.; Krishna, Sanjeev; Büscher, Philippe; Bisser, Sylvie; Ndung'u, Joseph Mathu; Sanchez, Jean-Charles // PLoS ONE;Jul2012, Vol. 7 Issue 7, p1 

    Background: Sleeping sickness, or human African trypanosomiasis (HAT), is a protozoan disease that affects rural communities in sub-Saharan Africa. Determination of the disease stage, essential for correct treatment, represents a key issue in the management of patients. In the present study we...

  • Chemotherapeutic Strategies Against Trypanosoma brucei: Drug Targets vs. Drug Targeting. L�scher, A.; de Koning, H. P.; M�ser, P. // Current Pharmaceutical Design;Feb2007, Vol. 13 Issue 6, p555 

    Trypanosoma brucei rhodesiense and T. b. gambiense are the causative agents of sleeping sickness, a fatal disease that affects 36 countries in sub-Saharan Africa. Nevertheless, only a handful of clinically useful drugs are available. These drugs suffer from severe side-effects. The situation is...

  • Human African trypanosomiasis in endemic populations and travellers. Blum, J.; Neumayr, A.; Hatz, C. // European Journal of Clinical Microbiology & Infectious Diseases;Jun2012, Vol. 31 Issue 6, p905 

    Human African trypanosomiasis (HAT) or sleeping sickness is caused by the protozoan parasites Trypanosoma brucei (T.b.) gambiense (West African form) and T.b. rhodesiense (East African form) that are transmitted by the bite of the tsetse fly, Glossina spp.. Whereas most patients in endemic...

  • African Trypanosomiasis Gambiense, Italy. Bisoffi, Zeno; Beltrame, Anna; Monteiro, Geraldo; Arzese, Alessandra; Marocco, Stefania; Rorato, Giada; Anselmi, Mariella; Viale, Pierluigi // Emerging Infectious Diseases;Nov2005, Vol. 11 Issue 11, p1745 

    African trypanosomiasis caused by Trypanosoma brucei gambiense has not been reported in Italy. We report 2 cases diagnosed in the summer of 2004. Theses cases suggest an increased risk for expatriates working in trypanosomiasis- endemic countries. Travel medicine clinics should be increasingly...

  • Protein phosphatase 5 is required for Hsp90 function during proteotoxic stresses in Trypanosoma brucei. Candace Jones; Sedrick Anderson; Ujjal Singha; Minu Chaudhuri // Parasitology Research;Apr2008, Vol. 102 Issue 5, p835 

    Abstract   Trypanosoma brucei, a parasitic protozoan that causes African trypanosomiasis in human and domestic animals, adapt in various environments during their digenetic life cycle. In this study, we found that Hsp90 is crucial for the survival of this parasite. Inhibition of Hsp90...

  • Gambiense sleeping sickness: re-emerging and soon untreatable? Van Nieuwenhove, Simon // Bulletin of the World Health Organization;2000, Vol. 78 Issue 11, p1283 

    Editorial. Comments on the return of sleeping sickness caused by Trypanosoma brucei gambiense. Deterioration and disruption of control activities; Problems on the implementation of active case detection and successful treatment; Gap between scientific progress and the implementation of...

  • Unravelling Human Trypanotolerance: IL8 is Associated with Infection Control whereas IL10 and TNFα Are Associated with Subsequent Disease Development. Ilboudo, Hamidou; Bras-Gonçalves, Rachel; Camara, Mamadou; Flori, Laurence; Camara, Oumou; Sakande, Hassane; Leno, Mamadou; Petitdidier, Elodie; Jamonneau, Vincent; Bucheton, Bruno // PLoS Pathogens;Nov2014, Vol. 10 Issue 11, p1 

    In West Africa, Trypanosoma brucei gambiense, causing human African trypanosomiasis (HAT), is associated with a great diversity of infection outcomes. In addition to patients who can be diagnosed in the early hemolymphatic phase (stage 1) or meningoencephalitic phase (stage 2), a number of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics